AI biotech iambic faces valuation challenges amid IPO plans

Wall Street is closely watching Iambic Therapeutics, an AI-driven biotech company set to go public this week. The firm aims to raise approximately $160 million at a $900 million valuation, following prior funding of around $350 million from venture capital firms. The company’s valuation has sparked debate, with some suggesting it may be undervalued compared to its competitor, Alphabet-backed Isomorphic Labs, which has not yet announced any clinical trials. A source revealed that Iambic was surprised by the Isomorphic report and considered adjusting its IPO target range. The valuation gap appears to stem from multiple factors, though the exact reasons remain unclear. Despite a narrowed IPO window, biotechs continue to pursue public listings, though pricing remains uncertain. Iambic’s platform claims to identify, develop, and commercialize drugs using AI, a goal that has yet to be fully realized.